Paper Details

  1. Home
  2. Paper Details

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Author: BahloJasmin, BergmannManuela, CramerPaula, DöhnerHartmut, EichhorstBarbara, ElterThomas, FinkAnna-Maria, FischerKirsten, GoedeValentin, HallekMichael, IsfortSusanne, KnebaMichael, KovacsGabor, LangeElisabeth, LangerbeinsPetra, PflugNatali, StauchMartina, StilgenbauerStephan, WendtnerClemens-Martin

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study analyzed the outcomes of 1,558 patients with chronic lymphocytic leukemia (CLL) and found that treatments combining chemotherapy and antibody medications were more effective than chemotherapy alone. While many patients with early relapse received aggressive combination therapies, there was no benefit compared to less intensive treatments. The analysis confirmed that chemoimmunotherapy is the most effective treatment for CLL.
Paper Details　
Original Abstract of the Article :
To evaluate the effect of first-line and subsequent therapies, the outcome of 1,558 patients with chronic lymphocytic leukemia from five prospective phase II/III trials conducted between 1999 and 2010 was analyzed. The 3-year overall survival rate was higher after first-line treatment with chemoimmu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825288/

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: Navigating the Desert of Treatment Options

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. This study examines the outcomes of different treatment strategies for CLL, comparing the effectiveness of various first-line therapies and relapse treatments. The researchers analyzed data from five prospective trials conducted by the German CLL Study Group (GCLLSG) to evaluate the impact of different treatment approaches on overall survival.

A Glimpse into the Desert of CLL Treatment: Mapping the Landscape

The study found that chemoimmunotherapies, which combine chemotherapy drugs with antibodies that target cancer cells, were associated with better overall survival rates compared to chemotherapy alone. The use of antibodies in any treatment line also led to longer median overall survival. However, the study also found that aggressive chemotherapy combinations did not offer any benefit in patients experiencing early relapse compared to less intensive therapies. This research highlights the need for a personalized approach to CLL treatment, considering the individual characteristics of each patient and tailoring therapy accordingly.

Navigating the Desert of CLL: A Personalized Approach

This study emphasizes the importance of ongoing research and clinical trials in CLL treatment. By continuously evaluating new therapies and strategies, healthcare professionals can improve patient outcomes and provide more effective treatments. This study also encourages a collaborative approach between clinicians and patients, ensuring that treatment decisions are made in a way that aligns with each patient's individual needs and preferences.

Dr.Camel's Conclusion

This study offers valuable insights into the treatment of CLL, reminding us that navigating the vast desert of treatment options requires a careful understanding of the disease, the available therapies, and the individual needs of each patient. The ongoing quest for more effective treatments continues, fueled by research and a dedication to improving patient outcomes.

Date :
  1. Date Completed 2016-08-01
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26315931

DOI: Digital Object Identifier

PMC4825288

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.